BB Biotech AG (BION.SW) stock: key figures, P/E, revenue and dividend
Health Care · Switzerland · ISIN CH0038389992
BB Biotech AG financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 111.00 m CHF | 76.00 m CHF |
| Gross profit | 111.00 m CHF | 76.00 m CHF |
| Operating income | 80.33 m CHF | 586.45 m CHF |
| EBIT | 84.00 m CHF | 586.00 m CHF |
| Net income | 75.00 m CHF | 578.00 m CHF |
| Diluted EPS – continuing operations | 1.39 CHF | 10.48 CHF |
Full history since 1995, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
More stocks
- Asmedia Technology Inc (5269.TW)
- Citizen Watch Co Ltd (7762.T)
- MAXIMUS, INC. (MMS)
- PARK NATIONAL CORP /OH/ (PRK)
- Japan Airport Terminal Co Ltd (9706.T)
- MAGNITE, INC. (MGNI)
- Azelis Group NV (AZE.BR)
- Park Hotels & Resorts Inc. (PK)
- Teekay Tankers Ltd (TNK)
- Shenzhen Huaqiang Industry Co Ltd (000062.SZ)
- Kyndryl Holdings, Inc. (KD)
- SPS COMMERCE INC (SPSC)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.